Introduction: The Persistent Challenge of Familial Hypercholesterolemia
Familial hypercholesterolemia (FH) represents one of the most common and clinically significant genetic conditions globally. Characterized by lifelong elevation of low-density lipoprotein cholesterol (LDL-C), FH serves as a primary driver for premature atherosclerotic cardiovascular disease (ASCVD). Despite our deep understanding of the genetic basis of this condition—primarily involving mutations in the LDLR, APOB, and PCSK9 genes—clinical identification and effective management remain disappointingly low. A recent landmark study published in JAMA Cardiology by Spinks et al. utilizes the ‘All of Us’ (AoU) Research Program to shed light on the prevalence, management, and real-world consequences of genotype-positive FH in a diverse US population.
Highlights
The study provides several critical insights into the current state of FH care in the United States:
- The prevalence of genotype-positive FH is approximately 0.35%, or 1 in every 287 individuals, mirroring global estimates but showing significant state-level variation.
- Genotype-positive status is associated with a nearly threefold increase in the odds of coronary artery disease compared to non-carriers.
- Clinical management is severely lacking: only 40% of identified FH carriers were prescribed statins, and only 38.4% had recent LDL-C measurements recorded.
- Target attainment is poor: fewer than 20% of FH carriers with existing ASCVD reached the guideline-recommended LDL-C target of <70 mg/dL.
Background: The Disease Burden of Lifelong Hypercholesterolemia
FH is an autosomal dominant disorder that results in a significant reduction in the liver’s ability to clear LDL-C from the blood. Unlike lifestyle-acquired hyperlipidemia, which typically manifests in middle age, individuals with FH are exposed to extremely high cholesterol levels from birth. This ‘cholesterol-year’ burden leads to the early development of atherosclerotic plaques. Without intervention, men with heterozygous FH often develop symptomatic CAD before age 55, and women before age 60. Despite the availability of highly effective lipid-lowering therapies (LLT), such as high-intensity statins, ezetimibe, and PCSK9 inhibitors, the condition remains underdiagnosed and undertreated, often referred to as a ‘hidden’ public health crisis.
Study Design and Methodology
The researchers conducted a cross-sectional analysis using data from the All of Us (AoU) Research Program, a massive longitudinal study sponsored by the National Institutes of Health. The study analyzed whole-genome sequencing (WGS) and electronic health record (EHR) data from 245,388 adult participants enrolled between May 2018 and July 2022.
Exposure and Classification
The primary exposure was the presence of pathogenic or likely pathogenic variants in three key genes: LDLR (low-density lipoprotein receptor), APOB (apolipoprotein B), and PCSK9 (proprotein convertase subtilisin/kexin type 9). These variants were manually classified using standard American College of Medical Genetics and Genomics (ACMG) criteria to ensure high specificity.
Outcome Measures
The study focused on four primary areas: demographic characteristics, lipid measurements, the prevalence of ASCVD (including CAD, peripheral artery disease, and stroke), and the quality of lipid management. Management was assessed based on the documentation of LLT and the achievement of LDL-C targets as defined by current clinical guidelines (e.g., <100 mg/dL for primary prevention and <70 mg/dL for secondary prevention).
Key Findings: A Stark Gap in Clinical Care
The results of the analysis provide a sobering look at the disconnect between genetic risk and clinical action.
Prevalence and Demographics
Among the 245,388 participants, 865 were identified as genotype-positive for FH, resulting in a prevalence of 0.35% (95% CI, 0.33%-0.38%). This translates to roughly 1 in 287 participants. Interestingly, the researchers noted geographic variation, suggesting that some regions may have higher clusters of certain genetic variants or different levels of screening efficacy.
Increased Risk of Cardiovascular Events
The clinical consequences of carrying an FH variant were profound. When compared to non-carriers, individuals with genotype-positive FH had significantly higher odds of several cardiovascular conditions:
- Coronary Artery Disease: Odds Ratio (OR) 2.91 (95% CI, 2.34-3.58).
- Peripheral Artery Disease: OR 1.51 (95% CI, 1.16-1.96).
- Transient Ischemic Attack or Stroke: OR 1.54 (95% CI, 1.11-2.09).
These findings reinforce the fact that a genetic diagnosis of FH is not merely a laboratory curiosity but a potent predictor of severe morbidity.
The Management Gap
Perhaps the most concerning findings related to how these high-risk individuals are managed in the current US healthcare system. Despite their genetic predisposition:
- Only 40% of genotype-positive individuals were prescribed statins.
- Only 38.4% had their LDL-C measured within the study timeframe.
- Only 30.1% of FH carriers achieved an LDL-C level of less than 100 mg/dL.
Even more alarming was the data regarding secondary prevention. Among individuals who already had established ASCVD and were on LLT, only 19.33% of FH carriers met the target LDL-C of <70 mg/dL, compared to 43.12% of non-carriers. This indicates that even when FH patients are identified and 'treated,' the intensity of therapy is often insufficient to overcome their genetic drive toward high cholesterol.
Expert Commentary: Moving Beyond the Genetic Label
The Spinks et al. study highlights a critical failure in the translation of genomic medicine to the bedside. While we have the technology to identify FH through whole-genome sequencing, the clinical infrastructure to act on this data is lagging. One of the primary issues identified is ‘therapeutic inertia’—the failure of clinicians to escalate treatment despite patients not meeting targets.
The Importance of Cascade Screening
Experts suggest that the identification of a ‘proband’ (the first person in a family identified with FH) should immediately trigger cascade screening of all first-degree relatives. Because FH is autosomal dominant, each child, sibling, or parent has a 50% chance of also having the condition. The All of Us data suggests we are missing these opportunities to intervene early in the lives of family members.
Barriers to Target Attainment
Why are targets not being met? Several factors are likely at play. First, the ‘baseline’ LDL-C in FH is so high that standard statin therapy is often insufficient. These patients frequently require triple therapy (statin + ezetimibe + PCSK9 inhibitor). Second, there is often a lack of awareness among both patients and primary care providers regarding the aggressive nature of FH. Finally, insurance barriers and the cost of newer therapies like PCSK9 inhibitors or inclisiran can prevent patients from accessing the most effective treatments.
Conclusion: A Call for Systematic Reform
This large-scale cohort study confirms that genotype-positive FH is a common and high-risk condition in the US population that is currently being managed suboptimally. The fact that the majority of FH carriers do not reach LDL-C targets—even after experiencing a cardiovascular event—is a clear signal that our current approach to lipid management is inadequate for genetic high-risk groups.
To improve outcomes, the medical community must move toward a more proactive, ‘genomics-first’ approach to screening, combined with more aggressive, guideline-directed medical therapy. Systems-level changes, such as automated EHR alerts for high LDL-C or genetic markers and improved access to lipid specialists, are essential to close the gap between genetic risk and clinical reality.
References
- Spinks C, Selvaraj MS, Robinson C, et al. Management and Consequences of Genotype-Positive Familial Hypercholesterolemia. JAMA Cardiol. 2026; doi:10.1001/jamacardio.2025.XXXX.
- Gidding SS, Champagne MA, de Ferranti SD, et al. The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. Circulation. 2015;132(22):2167-2192.
- Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J. 2013;34(45):3478-3490.